# Orlando Health Ventures

> Orlando Health Ventures is a VC fund backing Health Care and Medical Device. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 14
- Last investment: Jul 2026
- Lead investor: 50%
- Last updated: Aug 2026
- Website: https://www.orlandohealth.com/campaigns/strategic-innovations

Orlando Health Ventures is a VC fund focused on Health Care and Medical Device. Orlando Health Strategic Innovations will bring to life ideas, concepts and inventions from our team members and physicians.

## Contacts

5 contacts available for Orlando Health Ventures. Shizune tracks 2 team members at Orlando Health Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/orlando-health-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 64% |
| Medical Device | 7 | 50% |
| Medical | 5 | 36% |
| Biotechnology | 4 | 29% |
| Biopharma | 2 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 36% |
| Series C | 3 | 21% |
| Venture - Series Unknown | 2 | 14% |
| Series D | 1 | 7% |
| Funding Round | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 64% |
| United Kingdom | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bobby Helmedag | Managing Director | 5 | https://shizune.co/investors/profile/bobby-helmedag |
| David Strong | President & CEO | 2 | https://shizune.co/investors/profile/david-strong-0f8a |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| 410 Medical | 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $12M | Venture - Series Unknown | Jul 14, 2026 |  |
| 410 Medical | 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $14M | Series B | Mar 17, 2025 |  |
| Francis Medical | Francis Medical is a medical technology company developing therapeutic solutions to treat prostate, kidney, and bladder cancer. Francis Medical is developing a device for treating prostate cancer, the second most common cancer in American men, using a new platform to treat endourological cancers, water vapor technology. The thermal energy stored insterile water vapor is used to treat cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects. | $80M | Series C | Jan 07, 2025 |  |
| G.I. Windows | G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M |  | Nov 20, 2024 |  |
| G.I. Windows | G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M | Series B | Nov 20, 2024 |  |
| Endogenex | Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D. | $88M | Series C | Jun 25, 2024 |  |
| Arrivo BioVentures LLC | Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and otherregulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation. | $45.3M | Series B | Nov 29, 2023 |  |
| 410 Medical | 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $7.5M | Series B | May 25, 2023 |  |
| Sensydia | Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to goldstandard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring. | $8M | Venture - Series Unknown | May 09, 2023 |  |
| 410 Medical | 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $6.3M | Series B | Nov 10, 2022 |  |

10 of 14 investments shown.

## Co-investors
- [Rex Health Ventures](https://shizune.co/investors/profile/rex-health-ventures) — VC Fund, 7 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 5 deals together
- [OSF Healthcare System](https://shizune.co/investors/profile/osf) — VC Fund, 3 deals together
- [Solas BioVentures](https://shizune.co/investors/profile/solas-bioventures) — VC Fund, 3 deals together
- [WakeMed Health & Hospitals](https://shizune.co/investors/profile/wakemed-health-hospitals) — VC Fund, 3 deals together
- [Ballad Ventures](https://shizune.co/investors/profile/ballad-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Orlando Health Ventures invest in?

Orlando Health Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Orlando Health Ventures?

Public channels for Orlando Health Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Orlando Health Ventures?

The team at Orlando Health Ventures includes Bobby Helmedag (Managing Director) and David Strong (President & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co